{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-032748","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.123506+00:00","generated_at":"2026-05-18T21:50:25.560739+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sangamo reports positive Phase 1/2 data for Fabry gene therapy ST-920; BLA plan Q1 2026","bullets":["Mean annualized eGFR slope +1.965 at 52 weeks across 32 patients; +1.747 at 104 weeks for 19 patients.","All 18 patients on ERT at baseline withdrawn from ERT and remain off; α-Gal A activity sustained up to 4.5 years.","Reported eGFR slope compares favorably to Replagal (-2.2), Fabrazyme (-1.5), Galafold (-0.4) in published studies.","Significant SF-36 quality-of-life improvements: role-physical +14.8, vitality +9.6, bodily pain +9.0 at week 52.","No preconditioning required; most adverse events grade 1-2; no safety-related discontinuations."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-032748","json":"https://secwatch.observer/filing/0001628280-25-032748.json","markdown":"https://secwatch.observer/filing/0001628280-25-032748.md","text":"https://secwatch.observer/filing/0001628280-25-032748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828025032748/0001628280-25-032748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828025032748/sgmo-20250624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T21:50:25.560739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}